OKYO Pharma Limited is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc.
OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain.
OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer